Invesco Mortgage Capital Inc. faces challenges from rising interest rates and widening mortgage spreads, which have negatively impacted its common shares. However, the company's Series C preferred shares (IVR.PR.C) provide a roughly 7.8% yield with a floating-rate reset in 2027 and strong dividend coverage, making them more resilient than common stock. These preferred shares benefit from a declining share of the capital structure and have a substantial loss-absorption cushion from common equity. While not without risk, IVR.PR.C is considered a stable, income-focused investment with potential for yield improvement or modest capital gains at reset or redemption.
Invesco Mortgage Capital shares provide context for financial markets. For readers following Financials, here is Pluang's market snapshot as of Oct 16, 2026 22:12 WIB: 98 of 142 Financials stocks rose, 42 fell. Notable movers include WULF at USD 12.10 (-4.12%), PURR at USD 9.40 (-4.03%), and GEMI at USD 3.73 (-3.87%).
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
